Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

The effect of different maintenance therapies on outcome after autologous hematopoietic cell transplantation (AHCT) was analyzed in newly diagnosed multiple myeloma (NDMM) patients using global real-world data. NDMM patients transplanted between 2013 and 2017 were selected from the Worldwide Network for Blood and Marro...

Andrew J. Cowan, L. Gras, R. Cassano et al. · 0 citations
Review Open access Aug 2026

Real-world survey of hematopoietic stem cell transplantation in Japan using a nationwide administrative claims database

According to data from the Japanese registry managed by the Transplant Registry Unified Management Program, the number of autologous stem cell transplantations (auto-SCT) in 2018 was approximately 60% of that of allogeneic SCT (allo-SCT). The opposite trend has been reported in the United States. Thus, we hypothesized...

Y. Kuwatsuka, Kikue Sato, Y. Atsuta et al. · 0 citations
Review Open access Sep 2026

Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article.

This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations, and discusses emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, tha...

Abdulrahman Nasiri, R. El Fakih, C. Chabannon et al. · 1 citation
Open access Aug 2026

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.

Tatsuya Konishi, W. Kitamura, Shohei Mizuno et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.